 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | iCP-NI / Cellivery
Journal: Intracellular delivery of nuclear localization sequence peptide mitigates COVID-19 by inhibiting nuclear transport of inflammation associated transcription factors. (Pubmed Central) - Jan 8, 2024
Similarly, in hamsters infected with SARS-CoV-2, iCP-NI effectively protected the lung from inflammatory damage by reducing TNF-?, IL-6, and IL-17 levels. These promising results highlight iCP-NI's potential as a therapeutic approach for COVID-19-related lung complications and other inflammatory lung diseases.
- |||| iCP-NI / Cellivery
Trial suspension: iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects (clinicaltrials.gov) - May 17, 2023
P1, N=64, Suspended, Sponsor: Cellivery Therapeutics, Inc.
These promising results highlight iCP-NI's potential as a therapeutic approach for COVID-19-related lung complications and other inflammatory lung diseases. Recruiting --> Suspended
- ||| iCP-NI / Cellivery
New P1 trial: iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects (clinicaltrials.gov) - Feb 23, 2023
P1, N=64, Recruiting, Sponsor: Cellivery Therapeutics, Inc.
- iCP-NI / Cellivery
Intracellularly Delivered Nuclear Localization Sequence Attenuates The Severity Of COVID-19 By Inhibits Interaction Of Inflammatory Transcription Factors And Importins (Exhibit Hall; P331) - Apr 8, 2022 - Abstract #IMMUNOLOGY2022IMMUNOLOGY_1764;
Likewise, the levels of inflammatory cytokines such as TNF-α and IL-17A in the lungs are significantly decreased and thereby, the lung structures are protected from inflammation-mediated damages. As a result, the iCP-NI could be developed as a novel medicine to cure various inflammatory diseases including COVID-19.
- iCP-NI / Cellivery
Intracellular Delivery Of Nuclear Localization Signal Relieves Inflammatory Pulmonal Disease Through Regulating Immune System By Patient-Friendly Inhalant Formulation (Exhibit Hall; P193) - Apr 8, 2022 - Abstract #IMMUNOLOGY2022IMMUNOLOGY_1651;
Also, iCP-NI inhibited the recruitment of neutrophils (99.8%) and macrophages (99.6%) in BALF, and thereby induced the restoration of damaged lung tissue. In conclusion, iCP-NI has a significant therapeutic effect on COPD through immune system control and potential as a patient-friendly anti-inflammatory drug.